Introduction

With international operations in the U.S., Scotland and Sweden, we are a bio-pharmaceutical company engaged in the research, development, manufacture and commercialization of Multiferon ® (multi-subtype, human alpha interferon), which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, other niche cancer indications and selected infectious diseases.

We are a majority owned subsidiary of Viragen, Inc. (AMEX symbol “VRA”). Viragen currently owns approximately 77.0% of our outstanding common stock. We own 100% of ViraNative AB, our Swedish subsidiary, and 100% of Viragen (Scotland) Ltd., our...